First-line checkpoint inhibitors for wild-type advanced non-small-cell cancer: a pair-wise and network meta-analysis

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trials

Background:

• Non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related mortality.
• Checkpoint inhibitors have revolutionized NSCLC treatment, but optimal sequencing and combinations are under investigation.
• Identifying the most effective immunotherapy strategies is crucial for improving patient outcomes.

Purpose of the Study:

• To estimate the efficacy of various checkpoint inhibitor treatments in non-small-cell lung cancer.
• To rank the treatment effects of different immunotherapy regimens.
• To identify the optimal first-line treatment for advanced NSCLC with wild-type status.

Main Methods:

• A systematic review and meta-analysis of prospective randomized trials.
• Inclusion of nine trials encompassing 5504 patients.
• Utilized the p-score to rank treatment efficacy and compare outcomes.

Main Results:

• Pembrolizumab plus chemotherapy demonstrated the highest p-score (0.95), indicating superior efficacy.
• This combination was significantly more effective than pembrolizumab monotherapy (HR: 0.87; 95% CI: 0.79-0.95).
• While combination therapy increased grade 3-5 adverse events, it did not lead to higher rates of discontinuation or treatment-related death.

Conclusions:

• Pembrolizumab plus chemotherapy is likely the most effective treatment strategy for advanced NSCLC patients with wild-type tumors.
• This combination offers a significant survival benefit over pembrolizumab alone.
• The findings support the use of combination immunotherapy in specific NSCLC patient populations.